Press [ esc ] or close+





Blog

Strong Immune Response Rates Seen in Inovio's HIV Vaccine

07

Jun

Posted by

Category

Conferences

Strong Immune Response Rates Seen in Inovio's HIV Vaccine

HIV vaccine

An HIV vaccine is a vaccine which would either protect individuals who do not have HIV from contracting that virus, or otherwise may have a therapeutic effect for persons who have or later contract HIV/AIDS.

Vaccines are used to prevent many different infections in people. Vaccines work by causing a person's immune system (the body's defense against infections and cancer) to recognize and react to specific germs. If a person is exposed to one of those germs later, the vaccine may protect them from getting infected.

New preliminary results suggest promise for a potent vaccine against HIV.

Inovio Pharmaceuticals announced its HIV vaccine candidate PENNVAX-GP produced the highest overall levels of immune response rates ever seen in a human study for this type of treatment.

The trial is supported by the HIV Vaccines Trial Network (HVTN) and the National Institute of Allergy and Infectious Diseases (NIAID).

The study’s goal was to evaluate a four-dose regimen of PENNVAX-GP DNA vaccine in conjunction with an immune activator called IL-12. Investigators delivered the treatment via intradermal or intramuscular administration to 85 patients. Nine patients received a placebo as a control.

“These results are among the highest ever responses we’ve seen with an HIV vaccine, and they are remarkably consistent with our recent data reported from our Ebola, Zika and MERS clinical trials in terms of demonstrating nearly 100% vaccine response rates with very favorable safety profile. Furthermore, our newer and more tolerable intradermal vaccine delivery device showed that we can elicit very high immune responses at a much lower dose,” said Inovio’s President and CEO Dr. J. Joseph Kim, in a statement.

PENNVAX-GP is comprised of four HIV antigens engineered to cover multiple global HIV strains in order to generate an antibody and T-cell immune response to simultaneously prevent and treat the pathogen.

STDs & HIV - 2017 emphasizes on cutting-edge clinical, basic science, sociologic, and behavior-based investigations in HIV/AIDS and other sexually transmitted infections. Clinical trials, quantitative and qualitative analysis of pilot studies, comprehensive reviews, and case reports are presented from leading experts and scientists around the world.

STDs & HIV - 2017

06 November, 2017

Kuala lumpur, Malaysia

+1-619-471-1648

References:

https://www.dddmag.com

https://en.wikipedia.org/wiki/HIV_vaccine

http://hivinsite.ucsf.edu/

Meta title: 
Strong Immune Response Rates in Inovio's HIV Vaccine | Clyto Access

Add new comment

Filtered HTML

  • Web page addresses and e-mail addresses turn into links automatically.
  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.